Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have earned an average rating of “Moderate Buy” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $86.71.

Several equities research analysts recently weighed in on RARE shares. JPMorgan Chase & Co. upped their price objective on shares of Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $115.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, June 12th. TD Cowen lifted their price objective on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Robert W. Baird upped their target price on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the stock an “outperform” rating in a research note on Friday, May 31st. Finally, Stifel Nicolaus lifted their price target on Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research note on Friday, May 31st.

Insiders Place Their Bets

In other news, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total transaction of $441,270.00. Following the transaction, the executive vice president now owns 57,981 shares in the company, valued at $2,609,145. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.10, for a total transaction of $71,390.70. Following the completion of the transaction, the director now owns 7,248 shares in the company, valued at approximately $297,892.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Karah Herdman Parschauer sold 9,806 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $45.00, for a total transaction of $441,270.00. Following the completion of the transaction, the executive vice president now owns 57,981 shares in the company, valued at approximately $2,609,145. The disclosure for this sale can be found here. Insiders have sold 11,685 shares of company stock valued at $518,923 in the last ninety days. 5.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in Ultragenyx Pharmaceutical by 0.3% during the first quarter. Vanguard Group Inc. now owns 8,700,007 shares of the biopharmaceutical company’s stock worth $406,203,000 after purchasing an additional 26,575 shares during the period. RTW Investments LP grew its stake in shares of Ultragenyx Pharmaceutical by 27.4% in the 4th quarter. RTW Investments LP now owns 6,887,086 shares of the biopharmaceutical company’s stock valued at $329,340,000 after buying an additional 1,481,997 shares during the period. Wellington Management Group LLP increased its position in Ultragenyx Pharmaceutical by 0.4% in the 3rd quarter. Wellington Management Group LLP now owns 5,195,880 shares of the biopharmaceutical company’s stock valued at $185,233,000 after buying an additional 18,359 shares in the last quarter. Sands Capital Management LLC raised its stake in Ultragenyx Pharmaceutical by 59.8% during the 4th quarter. Sands Capital Management LLC now owns 4,118,008 shares of the biopharmaceutical company’s stock worth $196,923,000 after buying an additional 1,540,791 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its holdings in Ultragenyx Pharmaceutical by 3.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,568,873 shares of the biopharmaceutical company’s stock worth $166,632,000 after acquiring an additional 120,175 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 4.2 %

Shares of NASDAQ:RARE opened at $39.60 on Friday. Ultragenyx Pharmaceutical has a 12-month low of $31.52 and a 12-month high of $54.56. The company’s 50 day moving average price is $41.55 and its two-hundred day moving average price is $45.09. The firm has a market cap of $3.29 billion, a PE ratio of -4.93 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.72) by ($0.31). The company had revenue of $108.83 million for the quarter, compared to the consensus estimate of $116.03 million. Ultragenyx Pharmaceutical had a negative return on equity of 425.63% and a negative net margin of 138.58%. Ultragenyx Pharmaceutical’s revenue was up 8.3% on a year-over-year basis. During the same quarter last year, the business earned ($2.33) EPS. On average, research analysts expect that Ultragenyx Pharmaceutical will post -6.54 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.